Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Breast Cancer Treatment Based on Organ-like Culture
- Conditions
- Interventions
- Drug: TrastuzumabDrug: Doxorubicin HydrochlorideDrug: Epirubicin hydrochlorideDrug: FluorouracilDrug: PaclitaxelDrug: GemcitabineDrug: CisplatinDrug: Recombinant Human EndostatinDrug: Pirarubicin hydrochlorideDrug: PyrrolidineDrug: IxabepiloneDrug: Tamoxifen citrateDrug: Vinorelbine tartrateDrug: CarboplatinDrug: MethotrexateDrug: Eribulin mesylateDrug: Toremifene citrateDrug: AnastrozoleDrug: LetrozoleDrug: ExemestaneDrug: FulvestrantDrug: OlaparibDrug: BevacizumabDrug: Apatinib mesylateDrug: PattozumabDrug: CapecitabineDrug: Ear particlesDrug: Aidi InjectionDrug: Cyclophosphamide
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03925233
- Locations
- 🇨🇳
JingSu, Xi'an, Shaanxi, China
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 19
- Registration Number
- NCT03854903
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03803761
- Locations
- 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Sermonix Pharmaceuticals Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03781063
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸The Ohio State University - Comprehensive Cancer Center, Columbus, Ohio, United States
Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 59
- Registration Number
- NCT03772353
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Menarini Group
- Target Recruit Count
- 62
- Registration Number
- NCT03767335
- Locations
- 🇺🇸
Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States
🇧🇪UZ Leuven, Leuven, Belgium
🇺🇸Detroit Clinical Research Center, Farmington Hills, Michigan, United States
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 38
- Registration Number
- NCT03691493
- Locations
- 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 54
- Registration Number
- NCT03685331
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT03643510
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 93
- Registration Number
- NCT03633331
- Locations
- 🇺🇸
Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States
🇺🇸Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
🇺🇸Kootenai Cancer Center, Post Falls, Idaho, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.